'Paclitaxel' presentation slideshows

DRA. ROSSIO MEDINA B. ONCOLOGIA MEDICA 2014

1.41k views • 110 slides

995 views • 69 slides

Linda T. Vahdat, MD Medical Director, Breast Cancer Research Program Weill Cornell Medical College

Integration of Treatment Advances into Clinical Practice: Novel Microtubule-Targeting Agents in Metastatic Breast Cancer. Linda T. Vahdat, MD Medical Director, Breast Cancer Research Program Weill Cornell Medical College New York Presbyterian Hospital New York, NY. Program Goals.

919 views • 66 slides

Highlights of Metastatic Breast Cancer Research

Highlights of Metastatic Breast Cancer Research. ASCO 2007 : Highlights of Metastatic Breast Cancer Research. Single-Agent First-Line Therapy New data show improved clinical activity of nab -paclitaxel compared with docetaxel in patients with advanced breast cancer.

718 views • 50 slides

Update on Breast Cancer: ASCO 2004

Update on Breast Cancer: ASCO 2004. Hope S. Rugo, MD Clinical Professor of Medicine Director, Breast Oncology Clinical Trials Program University of California San Francisco Comprehensive Cancer Center. ASCO Update: Breast Cancer Chemotherapy. Neoadjuvant therapy

728 views • 49 slides

PROF. FRANCESCO COGNETTI REGINA ELENA NATIONAL CANCER INSTITUTE, ROME

TAXANES, GEMCITABINE AND MONOCLONAL ANTIBODIES ANTI-HER-2 AND THEIR COMBINED USE: WHAT IS THE BENEFIT IN TERMS OF RESPONSE QUALITY AND SURVIVAL?. PROF. FRANCESCO COGNETTI REGINA ELENA NATIONAL CANCER INSTITUTE, ROME. Rome, 16-18 December 2004. INTRODUCTION.

624 views • 46 slides

Clinical and pharmacological background

Clinical and pharmacological background. Microtubule stabilizing (and destabilizing) agents have relevant role in the treatment of breast cancer (and other tumors) They are natural compounds discovered serendipitously or in large-scale screens from plant, microbial, and marine sources

709 views • 40 slides

Martin B. Leon, MD for the Endeavor IV investigators

ENDEAVOR IV. Three-Year Follow-up from a Prospective Randomized Trial Comparing a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. Martin B. Leon, MD for the Endeavor IV investigators. Columbia University Medical Center

615 views • 37 slides

580 views • 29 slides

Bleomycin

Bleomycin. ???? ??????? ??? ????????? ???? 92/4/31. ??????? ?????? ????? ?????: ?.????. Taxanes. paclitaxel and docetaxel exert their cytotoxic effect by interfering with microtubule function . ( Pizzo 2011, p:325).

261 views • 26 slides

Abstract #LBA7511

Abstract #LBA7511. Results of a Randomized, Phase III Trial of nab -Paclitaxel and Carboplatin Compared With Cremophor-based Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Cancer.

343 views • 22 slides

Rationale for EGFR Inhibition in Combined Modality Therapy in NSCLC

Rationale for EGFR Inhibition in Combined Modality Therapy in NSCLC. Francisco Robert,M.D. UAB Cancer Center. Locally Advanced Stage III NSCLC. Represents approx 35-40% of cases During the past 2 decades,the management of these pts has undergone considerable change

360 views • 18 slides

KD Miller, M Wang, J Gralow, M Dickler, MA Cobleigh, EA Perez, TN Shenkier, NE Davidson

E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. KD Miller, M Wang, J Gralow, M Dickler, MA Cobleigh, EA Perez, TN Shenkier, NE Davidson

304 views • 17 slides

GOG0172: The Dings

GOG0172: The Dings. The recommended regimen is not feasible Substitution of carboplatin for cisplatin Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 Change paclitaxel infusion and/or schedule Need for 6 cycles not established Role of intraperitoneal delivery not established

456 views • 17 slides

Nanotechnology: Regulatory Challenges

Nanotechnology: Regulatory Challenges. Presented By: Phillip M. Buckler Vice President of Regulatory Affairs and Quality Kereos, Inc. St. Louis, MO. Presented at the FDA Nanotechnology Open Meeting October 10, 2006 Bethesda, MD. Definition of Nanotechnologies. Size ? 100nm

299 views • 10 slides

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons

PACCOCATH ISR. Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons. Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Bruno Scheller. PACCOCATH ISR: Background.

469 views • 8 slides

Karlan BY et al. Proc ASCO 2010;Abstract 5000.

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 386 Combined with Weekly Paclitaxel in Patients with Recurrent Ovarian Carcinoma. Karlan BY et al. Proc ASCO 2010;Abstract 5000. Introduction.

221 views • 8 slides

Gradishar WJ et al. SABCS 2009;Abstract 44.

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Gradishar WJ et al. SABCS 2009;Abstract 44. Introduction.

162 views • 8 slides

PD-1/PD-L1 ???? ???

172 views • 3 slides

INTRODUCTION

Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek , Jae-Woo So, Ji-Sook Hwang, Cheong-Weon Cho College of Pharmacy, Chungnam National University, Daejeon 305-764, South Korea. INTRODUCTION. 3. Surface tension.

90 views • 1 slides